Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 16/20 | 0.56 |
| ▸ | PSMB1 | P20618 | 12/20 | 0.51 |
| ▸ | PSMB2 | P49721 | 11/20 | 0.51 |
| ▸ | PSMB11 | A5LHX3 | 10/20 | 0.51 |
| ▸ | PSMA7 | O14818 | 10/20 | 0.51 |
| ▸ | PSMA1 | P25786 | 10/20 | 0.51 |
| ▸ | PSMA2 | P25787 | 10/20 | 0.51 |
| ▸ | PSMA3 | P25788 | 10/20 | 0.51 |
| ▸ | PSMA4 | P25789 | 10/20 | 0.51 |
| ▸ | PSMB8 | P28062 | 10/20 | 0.51 |
| ▸ | PSMB9 | P28065 | 10/20 | 0.51 |
| ▸ | PSMA5 | P28066 | 10/20 | 0.51 |
| ▸ | PSMB4 | P28070 | 10/20 | 0.51 |
| ▸ | PSMB6 | P28072 | 10/20 | 0.51 |
| ▸ | PSMB10 | P40306 | 10/20 | 0.51 |
| ▸ | PSMB3 | P49720 | 10/20 | 0.51 |
| ▸ | PSMA6 | P60900 | 10/20 | 0.51 |
| ▸ | PSMA8 | Q8TAA3 | 10/20 | 0.51 |
| ▸ | PSMB7 | Q99436 | 10/20 | 0.51 |
| ▸ | LONP1 | P36776 | 9/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20093548 | 1.00 | PSMB5 (0.56) | PSMB5PSMB1PSMB2PSMB11PSMA7 | |
| SCHEMBL14754748 | 1.00 | PSMB5 (0.56) | PSMB5PSMB1PSMB2PSMB11PSMA7 | |
| SCHEMBL13130829 | 1.00 | PSMB5 (0.56) | PSMB5PSMB1PSMB2PSMB11PSMA7 | |
| SCHEMBL464475 | 0.93 | PSMB5 (0.56) | PSMB5PSMB1PSMB2PSMB11PSMA7 | |
| SCHEMBL13130831 | 0.93 | PSMB5 (0.56) | PSMB5PSMB1PSMB2PSMB11PSMA7 | |
| SCHEMBL20093580 | 0.93 | PSMB5 (0.56) | PSMB5PSMB1PSMB2PSMB11PSMA7 | |
| SCHEMBL21558228 | 0.93 | PSMB5 (0.56) | PSMB5PSMB1PSMB2PSMB11PSMA7 | |
| SCHEMBL20093530 | 0.90 | PSMB5 (0.52) | PSMB5PSMB1PSMB2PSMB11PSMA7 | |
| SCHEMBL14712307 | 0.90 | PSMB5 (0.52) | PSMB5PSMB1PSMB2PSMB11PSMA7 | |
| SCHEMBL20365884 | 0.90 | PSMB5 (0.52) | PSMB5PSMB1PSMB2PSMB11PSMA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200046845-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. | 2020-02-13 | — | — | US | disclosed |
| US-20120213854-A1 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS | CERULEAN PHARMA INC. | 2012-08-23 | — | — | US | disclosed |
| US-20120202772-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | GLUCKSMANN ALEXANDRA (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120064107-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | CERULEAN PHARMA INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120004195-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. | 2012-01-05 | — | — | US | disclosed |
| US-20110178287-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202772-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | PSMG3, COPB1, PSMA6 | PSMB5 18/4885PSMB1 6/4885PSMB2 16/4885 |
| US-20120004195-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | PSMG3, COPB1, PSMA6 | PSMB5 18/4885PSMB1 6/4885PSMB2 16/4885 |
| US-20120064107-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | PHOSPHO1, SGMS1, SGMS2 | PSMB5 1149/4885PSMB1 1846/4885PSMB2 1429/4885 |
| US-20200046845-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CDR2, DDOST, GALC | PSMB5 1902/4885PSMB1 2386/4885PSMB2 2374/4885 |
| US-20120213854-A1 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS | HLA-DRB1, TSG101, IAPP | PSMB5 650/4885PSMB1 1054/4885PSMB2 856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.